The aim of this study was to investigate the efficacy and adverse effects of voriconazole in the treatment of invasive fungal infections (IFI) of the patients with blood diseases. The clinical manifestations and treatment of 69 cases of IFI patients with blood diseases were retrospectively analyzed. 39 cases were used voriconazole initially, 25 cases used voriconazole when fluconazol was inefficient. 5 cases used caspofungin and voriconazole together. In 69 patients with IFI, after treatment with voriconazole, 25 (36.23%) and 32 (46.38%) cases were clinically cured and obviously effective, respectively. The total effective rate was 82.60% (57/69). 6 (8.7%) and 6 (8.7%) cases were progressive and ineffective, respectively. During treatment, adverse reactions were found in 13 patients (18.84%, 13/69), including 3 cases with nausea, vomiting and increase of hepatic enzymes, 5 cases with rash, and 5 patients with visual disturbances and eye pain. Expectant treatment was treated on them, followed by continued use of voriconazole. The symptom was improved within 1 week. Voriconazole is an efficacious and well to le rated antifungal agent in the treatment of IFI in patients with hematologic disease.